New combo aims to boost CAR-T power against stubborn lymphoma

NCT ID NCT06553872

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding the drug pirtobrutinib to a CAR-T cell therapy (brexucabtagene autoleucel) works better than CAR-T alone for people with mantle cell lymphoma that has come back or stopped responding to treatment. About 60 adults will be randomly assigned to receive the combo or just CAR-T. Researchers will track how long the cancer stays away and watch for serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pirtobrutinib and brexucabtagene autoleucel (CAR-T cell therapy)
What this could lead to: If successful, this combination could improve how long patients with hard-to-treat mantle cell lymphoma stay cancer-free after treatment.
What could go wrong: This is a mid-stage trial with only 60 people, so results may not apply to everyone. CAR-T therapy can cause serious side effects like immune overreaction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Stanford Cancer Center
NOT_YET_RECRUITING

Stanford, California, 94305, United States
Univ of Miami - Sylvester Comprehensive Cancer Center
RECRUITING

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.